Analyst Price Targets — NBIX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 17, 2026 10:23 am | — | Wells Fargo | $200.00 | $171.55 | TheFly | Neurocrine price target raised to $200 from $175 at Wells Fargo |
| July 13, 2026 1:52 pm | — | Truist Financial | $200.00 | $175.16 | TheFly | Neurocrine price target raised to $200 from $155 at Truist |
| July 13, 2026 12:20 pm | — | BMO Capital | $170.00 | $173.89 | TheFly | Neurocrine price target raised to $170 from $144 at BMO Capital |
| July 13, 2026 12:05 pm | — | Wedbush | $185.00 | $173.73 | TheFly | Neurocrine price target raised to $185 from $176 at Wedbush |
| July 7, 2026 11:21 am | Brian Abrahams | RBC Capital | $195.00 | $174.10 | TheFly | Neurocrine price target raised to $195 from $183 at RBC Capital |
| June 30, 2026 9:59 am | — | UBS | $208.00 | $170.00 | TheFly | Neurocrine price target raised to $208 from $182 at UBS |
| June 2, 2026 9:07 am | Corinne Johnson | Goldman Sachs | $213.00 | $161.00 | StreetInsider | Goldman Sachs Resumes Neurocrine Bio. (NBIX) at Buy |
| May 21, 2026 8:23 pm | Jeffrey Walch | Bernstein | $221.00 | $155.50 | TheFly | Neurocrine initiated with an Outperform at Bernstein |
| May 6, 2026 11:36 am | — | Oppenheimer | $230.00 | $135.06 | TheFly | Neurocrine price target raised to $230 from $220 at Oppenheimer |
| May 6, 2026 10:57 am | — | Piper Sandler | $207.00 | $135.06 | TheFly | Neurocrine price target raised to $207 from $190 at Piper Sandler |
Latest News for NBIX
NVIDIA, Neurocrine and Ball screen well for earnings growth and rising estimates, highlighting stocks with improving profit expectations.
Neurocrine Biosciences (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Biopharmaceutical firm Neurocrine Biosciences, Inc. (NBIX) up over 35% in a year and 17% since outlier inflows in May.
Conference Call and Webcast Scheduled for Thursday, July 30 SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NBIX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.